Activity of front-line FOLFIRINOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC).

4057 Background: The PRODIGE/ACCORD trial recently established FFX as a treatment option for good performance status (PS) pts with stage IV PC (Conroy et al, NEJM 2011). We evaluated the activity and toxicity associated with FFX therapy in pts with advanced PC treated at MSKCC outside of a clinical trial. Methods: 80patients (pts) treated withFFX as 1st-line therapyat MSKCC between 07/1/10 and 12/30/11, were identified from an institutional database (prior IRB approval). Records were reviewed for demographic, treatment, toxcity, and response data. Results: 61 and 19 pts received FFX for stage IV and III PAC respectively. Demographics and outcomes are summarized in the table. Median starting dose of FFX was 80% of that used in the PRODIGE/ACCORD trial. Median overall survival (OS) was 12.5 months (mo) (95% CI 9.5–15.5) in pts treated with 1st line FFX for stage IV PAC and 13.7 mo (95% CI 11.3–15.8) in pts with stage III PAC. 68% of pts with stage IV PAC who discontinued FFX for disease progression (PD) or ...